SUPPLEMENTAL FIGURE 1a. Overall Survival of cT1-2, cN1, pN0, M0 NSCLC Patients, Stratified by Open vs VATS Lobectomy
SUPPLEMENTAL FIGURE 1b. Overall Survival of cT1-2, cN1, pN2, M0 NSCLC Patients, Stratified by Open vs VATS Lobectomy
Log-rank P = 0.43
Log-rank P = 0.80
SUPPLEMENTAL FIGURE 1c. Overall Survival of cT1-2, cN1, pN1, M0 NSCLC Patients, Stratified by Open vs VATS Lobectomy
Log-rank P = 0.37
SUPPLEMENTAL FIGURE 2. Histogram of Propensity Scores After Matching
SUPPLEMENTAL FIGURE 3. Absolute Standardized Differences of Means for Confounding Variables
before and after Propensity Score Matching
SUPPLEMENTAL FIGURE 4. Overall Survival of Open/VATS Converted to Open vs VATS Lobectomy for cT1-2, cN1, pN0, M0 NSCLC: Analysis of the Propensity Score-matched Dataset
SUPPLEMENTAL FIGURE 5. Overall Survival of cT1-2, N1, M0 NSCLC Patients with No Comorbidities, Stratified by Open vs VATS Lobectomy: Propensity Score-matched Analysis
Log-rank P = 0.61
P = 0.99 by stratified log-rank
SUPPLEMENTAL TABLE 1: Baseline Characteristics after Propensity Score Matching of cT1-2, N1, M0 NSCLC Patients with No Comorbidities
Patient Characteristics
Open (N=155)
VATS (N=155)
Standardized Differences
(%)
Age (years, IQR) 66 (57,72) 66 (59,73) 3.5
Female, n (%) 73 (47.1%) 82 (52.9%) 11.6
Race, n (%)
White 130 (83.9%) 134 (86.5%) 7.5
Black 17 (11.0%) 14 (9.0%) -6.6
Other <10 <10 -3.2
Education above median, n (%) 90 (58.1%) 88 (56.8%) 9.5
Income above median, n (%) 102 (65.8%) 98 (63.2%) -8.4
Facility type, n (%)
Community cancer program <10 <10 2.9
Comprehensive community cancer program 74 (47.7%) 72 (46.5%) -2.6
Academic/research program 61 (39.4%) 62 (40.0%) 1.4
Integrated network cancer program 15 (9.7%) 15 (9.7%) 0.0
Insurance, n (%)
Private 61 (39.4%) 62 (40.0%) 1.3
Medicaid <10 <10 -6.0
Medicare 76 (49.0%) 78 (50.3%) 2.6
Other government <10 <10 -4.7
Uninsured <10 <10 0.0
Clinical T status, n (%)
T1 78 (50.3%) 82 (52.9%) 5.2
T2 77 (49.7%) 73 (47.1%) -5.2
Tumor size (cm), mean (SD) 2.79 (1.01) 2.83 (1.10) 3.4
Tumor Location, n (%)
Right upper lobe 54 (34.8%) 56 (36.1%) 2.7
Right middle lobe <10 <10 2.7
Right lower lobe 31 (20.0%) 34 (21.9%) 4.8
Left upper lobe 46 (29.7%) 40 (25.8%) -8.9
Left lower lobe 16 (10.3%) 16 (10.3%) 0.0
Histology, n (%)
Adenocarcinoma 97 (62.6%) 101 (65.2%) 5.4
Squamous 43 (27.7%) 39 (25.2%) -5.8
Large cell <10 <10 0.0
Adenosquamous <10 <10 0.0
Grade, n (%)
Well differentiated 12 (7.7%) 12 (7.7%) 0.0
Moderately differentiated 69 (38.7%) 63 (40.7%) 3.9
Poorly differentiated 79 (51.0%) 76 (49.0%) -3.9
Undifferentiated/anaplastic <10 <10 0.0
Distance to facility (miles, IQR) 9.7 (4.4,18.5) 10 (4.3,27.4) 1.4
SUPPLEMENTAL TABLE 2: Perioperative and Postoperative Data after Propensity Score Matching of cT1-2, N1, M0 NSCLC Patients with No Comorbidities
* Data available for 39 patients
** Data available for 165 patients
*** Data available for 301 patients
**** Data available for 299 patients Variable
Open (N=155)
VATS
(N=155) P
Treatment specifics
Days to definitive surgery (IQR) 34 (15,56) 27 (11,43) 0.029 Days to adjuvant therapy (IQR)
Adjuvant radiotherapy* 143 (81,200) 95.5 (55,152) 0.036 Adjuvant chemotherapy** 80 (61,112) 75 (53.5,101) 0.19
Adjuvant therapy, n (%) 0.58
Adjuvant radiotherapy <10 <10
Adjuvant chemotherapy 75 (48.4%) 68 (43.9%) Adjuvant chemoradiation 13 (8.4%) 20 (12.9%)
Conversion to open surgery, n (%) N/A 34 (21.9%) N/A
Surgical endpoints
Nodes removed (IQR) 11 (6,16) 10 (7,19) 0.66
Surgical margins, n (%) 0.91
Negative 144 (92.9%) 145 (93.6%)
Positive margin-microscopic <10 <10 Positive margin-macroscopic <10 <10
Short-term outcomes
30-day mortality, n (%) <10 <10 0.16
30-day readmission, n (%) 12 (7.8%) <10 0.32
Hospital length of stay (days, IQR) 6 (4,8) 5 (3,7) 0.008
Tumor characteristics
Pathological T status, n (%)*** 0.28
T0 (in situ) 0 (0.0%) 0 (0.0%)
T1 67 (45.0%) 66 (43.4%)
T2 72 (48.3%) 81 (53.3%)
T3 <10 <10
T4 <10 0 (0.0%)
Pathologic N status, n (%)**** 0.36
N0 28 (18.8%) 39 (25.8%)
N1 101 (67.8%) 92 (60.9%)
N2 19 (12.8%) 20 (13.3%)
N3 0 (0.0%) 0 (0.0%)
SUPPLEMENTAL TABLE 3. Open vs. VATS Converted to Open Lobectomy for Patients With cT1-2, N1, M0 NSCLC: Baseline Characteristics
Patient characteristics
Total Cohort Propensity Score-matched Analysis
Open (N=1,204)
VATS Converted to
Open (N=73)
Standardized Differences
(%) P
Open (N=70)
VATS Converted to
Open (N=70)
Standardized Differences
(%) Age (years, IQR) 67 (59,73) 66 (59,73) 0.5 0.71 67.5 (61,72) 65 (59,73) -10.0
Female, n (%) 563 (46.8%) 28 (38.4%) 7.8 0.16 27 (38.6%) 27 (38.6%) 0.0
Race, n (%) 0.53
White 1,052 (87.4%) 61 (83.6%) -2.5 60 (85.7%) 58 (82.9%) -8.5
Black 115 (9.6%) <10 0.3 <10 <10 0.0
Other 37 (3.1%) <10 4.1 <10 <10 15.7
CDCC score, n (%) 0.08
0 592 (49.2%) 35 (47.9%) -1.6 28 (40.0%) 34 (48.6%) 17.1
1 414 (34.4%) 20 (27.4%) 1.3 20 (28.6%) 19 (27.1%) -3.0
2 160 (13.3%) 12 (16.4%) -0.7 16 (22.9%) 12 (17.1%) -17.0
3+ 38 (3.2%) <10 2.5 <10 <10 8.0
Education, n (%) 0.97
>21% 215 (17.9%) 13 (17.8%) -10.5 12 (17.1%) 11 (15.7%) -3.9
13% to 20.9% 359 (29.9%) 23 (31.5%) 0.7 20 (28.6%) 22 (31.4%) 6.2
7% to 12.9% 409 (34.1%) 23 (31.5%) 1.7 24 (34.3%) 23 (32.9%) -3.0
Less than 7% 217 (18.1%) 14 (19.2%) 7.0 14 (20.0%) 14 (20.0%) 0.0
Income above median, n (%) 0.23
< $38,000 248 (20.7%) 12 (16.4%) -13.1 14 (20.0%) 11 (15.7%) -11.2
$38,000 to $47,999 324 (27.0%) 19 (26.0%) -8.8 17 (24.3%) 19 (27.1%) 6.6
$48,000 to $62,999 331 (27.6%) 28 (38.4%) 8.9 26 (37.1%) 26 (37.1%) 0.0
$63,000 or greater 297 (24.8%) 14 (19.2%) 10.8 13 (18.6%) 14 (20.0%) 3.2
Facility type, n (%) 0.94
Community cancer program 76 (6.3%) <10 -7.5 <10 <10 12.5
Comprehensive community cancer program
617 (51.4%) 36 (49.3%) -14.9 34 (48.6%) 33 (47.1%) -2.9
Academic/research program 359 (29.9%) 24 (32.9%) 24.9 27 (38.6%) 24 (34.3%) -9.0 Integrated network cancer
program
148 (12.3%) <10 -8.5 <10 <10 -9.1
Insurance, n (%) 0.54
Private 377 (31.3%) 24 (32.9%) 5.5 23 (32.9%) 24 (34.3%) 3.0
Medicaid 69 (5.7%) <10 -2.5 <10 <10 0.0
Medicare 707 (58.7%) 38 (52.1%) -4.3 37 (52.9%) 37 (52.9%) 0.0
Other government 15 (1.3%) <10 3.9 <10 <10 -23.3
Uninsured 27 (2.2%) <10 -5.6 <10 <10 0.0
Clinical T status, n (%) 0.17
T1 594 (49.3%) 42 (57.5%) 5.4 41 (58.6%) 41 (58.6%) 0.0
T2 610 (50.7%) 31 (42.5%) -5.4 29 (41.4%) 29 (41.4%) 0.0
Tumor size (cm), mean (SD) 2.99 (1.07) 2.72 (1.08) -9.6 0.03 2.70 (1.5) 2.68 (1.07) -1.6
Tumor Location, n (%) 0.68
Right upper lobe 419 (36.0%) 23 (12.3%) 1.0 27 (38.6%) 23 (32.9%) -12.0
Right middle lobe 72 (6.2%) <10 -4.2 <10 <10 0.0
Right lower lobe 203 (17.5%) 12 (16.4%) 8.4 10 (14.3%) 11 (15.7%) 3.7
Left upper lobe 292 (25.1%) 24 (32.9%) 2.5 24 (34.3%) 23 (32.9%) -3.3
Left lower lobe 177 (15.2%) <10 -9.1 <10 <10 16.5
Histology, n (%) 0.53
Adenocarcinoma 700 (58.1%) 48 (65.8%) 3.1 47 (67.1%) 47 (67.1%) 0.0
Squamous 418 (34.7%) 20 (27.4%) -9.0 21 (30.0%) 19 (27.1%) -6.1
Large cell 46 (3.8%) <10 4.6 <10 <10 7.3
Adenosquamous 40 (3.3%) <10 9.3 <10 <10 7.2
Grade, n (%) 0.12
Well differentiated 61 (5.1%) <10 0.3 <10 <10 12.8
Moderately differentiated 576 (47.8%) 29 (39.7%) -10.3 30 (42.9%) 28 (40.0%) -5.7 Poorly differentiated 517 (42.9%) 34 (46.6%) 9.2 34 (48.6%) 33 (47.1%) -2.9
Undifferentiated/anaplastic 18 (1.5%) <10 3.9 <10 <10 10.8
Distance to facility (miles, IQR) 10.7 (4.6,26.6) 7.6 (4.2,16.5) -3.7 0.09 9.85 (5,21.5) 8 (3.9,16.5) 6.4